CD274 and ovarian cancer: Another clinical trial, TOPACIO, investigated the efficacy of the PARPi niraparib and the PD-L1 inhibitor pembrolizumab in platinum-resistant advanced breast cancers and recurrent ovarian cancers, independent of their HR proficiency.